A carregar...
Is combining an anticholinergic with a cholinesterase inhibitor a good strategy for high-level CNS cholinesterase inhibition?
The currently approved cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) produce gastrointestinal toxicity which limits dosing to that which produces only about 25% to 35% CNS cholinesterase inhibition in Alzheimer’s patients undergoing treatment, below the minimum therapeutic tar...
Na minha lista:
| Publicado no: | J Alzheimers Dis |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6839449/ https://ncbi.nlm.nih.gov/pubmed/31476160 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JAD-190626 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|